초록 ▼

The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass method

The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.

대표청구항 ▼

What is claimed is: 1. A method of inducing a cytostatic effect on cancer cells in a subject, comprising: administering an effective amount of an isolated cucurbitacin to said subject, to induce said cytostatic effect in said cancer cells. 2. The method of claim 1, wherein said cucurbitacin comp

What is claimed is: 1. A method of inducing a cytostatic effect on cancer cells in a subject, comprising: administering an effective amount of an isolated cucurbitacin to said subject, to induce said cytostatic effect in said cancer cells. 2. The method of claim 1, wherein said cucurbitacin comprises cucurbitacin B, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin B at a concentration of 5.8 nM to 164 nM. 3. The method of claim 1, wherein said cucurbitacin comprises cucurbitacin D, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin D at a concentration of 14 nM to 324 nM. 4. The method of claim 1, wherein said cancer cells are selected from the group consisting of leukemia cells, melanoma cells, breast cancer cells, brain cancer cells, colon cancer cells, lung cancer cells, ovary cancer cells, renal cancer cells, prostate cancer cells and kidney cancer cells. 5. The method of claim 4, wherein said cucurbitacin comprises cucurbitacin B, wherein said cancer cells are prostate cancer cells, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin B at a concentration of 17 nM. 6. The method of claim 4, wherein said cucurbitacin comprises cucurbitacin D, wherein said cancer cells are melanoma cells, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin D at a concentration of 60 nM. 7. A method of inducing cell cycle arrest in cancer cells in a subject, comprising: activating the MAPK signaling pathway by administering an effective amount of an isolated cucurbitacin to said subject, to induce cell cycle arrest in said cancer cells. 8. The method of claim 7, wherein said cancer cells are selected from the group consisting of leukemia cells, melanoma cells, breast cancer cells, brain cancer cells, colon cancer cells, lung cancer cells, ovary cancer cells, renal cancer cells, prostate cancer cells and kidney cancer cells. 9. The method of claim 8, wherein said cucurbitacin comprises cucurbitacin B, and wherein said cancer cells are leukemia cells. 10. The method of claim 8, wherein said cucurbitacin comprises cucurbitacin D, and wherein said cancer cells are brain cancer cells. 11. A method of inducing apoptosis in cancer cells in a subject, comprising: activating the PARP pathway by administering from 6 nM to 350 nM of an isolated cucurbitacin to said subject, to induce apoptosis in said cancer cells. 12. The method of claim 11, wherein said cancer cells are selected from the group consisting of leukemia cells, melanoma cells, breast cancer cells, brain cancer cells, colon cancer cells, lung cancer cells, ovary cancer cells, renal cancer cells, prostate cancer cells and kidney cancer cells. 13. The method of claim 12, wherein said cucurbitacin comprises cucurbitacin B, wherein said cancer cells are colon cancer cells, and wherein said administering comprises contacting said cancer cells with cucurbitacin B at a concentration of 5.8 nM to 64.5 nM. 14. The method of claim 12, wherein said cucurbitacin comprises cucurbitacin B, wherein said cancer cells are breast cancer cells, and wherein said administering comprises contacting said cancer cells with cucurbitacin B at a concentration of 18.7 nM to 110.7 nM. 15. The method of claim 12, wherein said cucurbitacin comprises cucurbitacin D, wherein said cancer cells are ovary cancer cells, and wherein said administering comprises contacting said cancer cells with cucurbitacin D at a concentration of 90.6 nM to 154.4 nM. 16. The method of claim 12, wherein said cucurbitacin comprises cucurbitacin D, wherein said cancer cells are prostate cancer cells, and wherein said administering comprises contacting said cancer cells with cucurbitacin D at a concentration of 92.3 nM to 105.7 nM.